Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
BRAF+
•
Langerhans Cell Histiocytosis
Do you recommend using cell-free BRAFV600E to track response to therapy in pediatric patients with langerhans cell histiocytosis?
Related Questions
At what point should surgical intervention be considered for vestibular schwannomas or other tumors in pediatric NF2 patients?
Would you recommend a specific workup or change in management for patients with severe, persistent deficits from methotrexate leukoencephalopathy?
How do you treat factor XI deficient patients with surgery or trauma related bleeding?
What is your approach to screening a cancer survivor for iron overload, and what is your treatment of choice?
How can the integration of MRD assessments into treatment protocols be optimized to improve risk stratification and therapy decisions in T-ALL?
What is your strategy for optimizing hydroxyurea dosage in patients with symptomatic sickle cell disease, particularly for genotypes HbSS and HbS/Beta thal?
What approach do you use when treating adult diffuse gliomas with H3-G34 mutations, now classified into their own category under the 2021 glioma guidelines?
Based on the FIREFLY-1 data, would you consider using tovorafenib monotherapy front-line in pediatric patients who have low grade gliomas that are only amenable to subtotal resection or are unresectable?
How do different inflammatory markers like CRP and ferritin contribute differently, if at all, to the monitoring of CART neurotoxicity?
How do you counsel sickle cell patients on the use of G-CSF to treat neutropenia from other causes, like malignancy?
